{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:44:08Z","timestamp":1791254648336,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1997,4,1]],"date-time":"1997-04-01T00:00:00Z","timestamp":859852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[1997,4]]},"DOI":"10.1006\/phrs.1997.0124","type":"journal-article","created":{"date-parts":[[2002,10,7]],"date-time":"2002-10-07T00:00:15Z","timestamp":1033948815000},"page":"241-256","source":"Crossref","is-referenced-by-count":135,"title":["A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG"],"prefix":"10.1006","volume":"35","author":[{"given":"EMILIO","family":"PERUCCA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/phrs.1997.0124_FR970124RF1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/106002809402801011","article-title":"Gabapentin: A new agent for the management of epilepsy","volume":"28","author":"Andrews","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.1006\/phrs.1997.0124_FR970124RF2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199141060-00007","article-title":"Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control","volume":"41","author":"Grant","year":"1991","journal-title":"Drugs"},{"key":"10.1006\/phrs.1997.0124_FR970124RF3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","article-title":"Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"10.1006\/phrs.1997.0124_FR970124RF4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-199346030-00007","article-title":"Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"10.1006\/phrs.1997.0124_FR970124RF5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2165\/00003495-199346010-00009","article-title":"Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"10.1006\/phrs.1997.0124_FR970124RF6","series-title":"Antiepileptic Drugs","author":"Levy","year":"1995"},{"key":"10.1006\/phrs.1997.0124_FR970124RF7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/00003495-199345060-00008","article-title":"Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"10.1006\/phrs.1997.0124_FR970124RF8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/phrs.1993.1113","article-title":"The clinical pharmacology of the new antiepileptic drugs","volume":"28","author":"Perucca","year":"1993","journal-title":"Pharm Res"},{"key":"10.1006\/phrs.1997.0124_FR970124RF9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2165\/00003495-199345050-00010","article-title":"Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy","volume":"45","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"10.1006\/phrs.1997.0124_FR970124RF10","series-title":"New Antiepileptic Drugs","author":"Pisani","year":"1991"},{"key":"10.1006\/phrs.1997.0124_FR970124RF11","series-title":"A Textbook of Epilepsy","article-title":"Clinical pharmacology and medical treatment","author":"Richens","year":"1993"},{"key":"10.1006\/phrs.1997.0124_FR970124RF12","series-title":"Potential antiepileptic drugs: Topiramate","author":"Ben-Menachem","year":"1995"},{"key":"10.1006\/phrs.1997.0124_FR970124RF13","first-page":"648","article-title":"Anticonvulsant activity of McN-4853 (M)1,3:4,5-bis-O-(LD","volume":"27","author":"Gardocki","year":"1986","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1358\/dof.1989.014.04.85087","article-title":"Topiramate","volume":"14","author":"Maryanoff","year":"1989","journal-title":"Drugs of the Future"},{"key":"10.1006\/phrs.1997.0124_FR970124RF15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/jm00388a023","article-title":"Anticonvulsant O-alkyl-sulfamates in 2,3: 4,5-bis-O-(1-methylethylidene)-beta-D","volume":"30","author":"Maryanoff","year":"1987","journal-title":"J Med Chem"},{"key":"10.1006\/phrs.1997.0124_FR970124RF16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","article-title":"Topiramate: Preclinical evaluation of a structurally novel anticonvulsant","volume":"35","author":"Shank","year":"1994","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF17","first-page":"1","article-title":"Anticonvulsant activities and properties of topiramate","volume":"58 (suppl 1)","author":"Kimishima","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0014-2999(94)90373-5","article-title":"Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA\/2 mice","volume":"24","author":"Nakamura","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0920-1211(95)00105-0","article-title":"Topiramate: A potent anticonvulsant in the amygdala-kindled rat","volume":"24","author":"Wauquier","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1006\/phrs.1997.0124_FR970124RF20","first-page":"1","article-title":"Preclinical profile of topiramate, a novel anticonvulsant","volume":"1","author":"Shank","year":"1995","journal-title":"Adv AED Ther"},{"key":"10.1006\/phrs.1997.0124_FR970124RF21","first-page":"370","article-title":"Anticonvulsant action of acetazolamide, alone and in combination with ammonium chloride","volume":"14","author":"Millichap","year":"1955","journal-title":"Fed Proc"},{"key":"10.1006\/phrs.1997.0124_FR970124RF22","first-page":"33","article-title":"Effects of carbonic anhydrase inhibition on brain excitability","volume":"122","author":"Koch","year":"1958","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1006\/phrs.1997.0124_FR970124RF23","first-page":"7","article-title":"Investigation of the mechanism of topiramate's anticonvulsant activity","volume":"32","author":"Shank","year":"1991","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF24","first-page":"123","article-title":"Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons","volume":"34 (suppl 2)","author":"Coulter","year":"1993","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF25","first-page":"38","article-title":"Effects of topiramate on sustained repetitive firing and low Mg2+","volume":"36 (suppl 4)","author":"Sombati","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF26","first-page":"51","article-title":"Effects induced by topiramate on sodium electrogenesis in mammalian central neurons","volume":"37 (suppl 4)","author":"Avoli","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.410200202","article-title":"Phenytoin: Mechanisms of its anticonvulsant action","volume":"20","author":"Yaari","year":"1986","journal-title":"Ann Neurol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF28","first-page":"122","article-title":"The novel anticonvulsant topiramate enhances GABA-mediated chloride flux","volume":"34 (suppl 2)","author":"Brown","year":"1993","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF29","first-page":"34","article-title":"The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons","volume":"36 (suppl 4)","author":"White","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF30","first-page":"48","article-title":"Topiramate modulates GABA receptor responses in Xenopus oocytes expressing several recombinant receptor subunit combinations","volume":"36 (suppl 4)","author":"Gordey","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF31","first-page":"38","article-title":"Topiramate selectively blocks kainate currents in cultured hippocampal neurons","volume":"36 (suppl 4)","author":"Severt","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0021-5198(19)48774-X","article-title":"Inhibition of excessive releases of excitatory aminoacids in hippocampus of spontaneously epileptic rat (SER) by topiramate (KW-6485)","volume":"58 (suppl 1)","author":"Kanda","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF33","first-page":"74","article-title":"Preclinical evaluation of McN-5707 as a potential antidepressant","volume":"242","author":"Shank","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1006\/phrs.1997.0124_FR970124RF34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-199631010-00003","article-title":"The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on Topiramate, zonisamide and tiagabine","volume":"31","author":"Perucca","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1006\/phrs.1997.0124_FR970124RF35","first-page":"1029","article-title":"Estimation of the absolute bioavailability of topiramate in humans without intravenous data","volume":"34","author":"Nayak","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF36","first-page":"7","article-title":"Pharmacokinetics of topiramate","volume":"1","author":"Doose","year":"1995","journal-title":"Adv Antiepil Drug Ther"},{"key":"10.1006\/phrs.1997.0124_FR970124RF37","first-page":"662","article-title":"Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans","volume":"29","author":"Easterling","year":"1988","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF38","first-page":"149","article-title":"Phase I study of topiramate in Japanese subjects","volume":"36 (suppl 3)","author":"Takahashi","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF39","unstructured":"Perucca, E, Doose, DR, The clinical pharmacokinetics of topiramate, a new antiepileptic drug, J Clin Pharmacol, (in press)"},{"key":"10.1006\/phrs.1997.0124_FR970124RF40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1528-1157.1996.tb06032.x","article-title":"Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs","volume":"37 (suppl 2)","author":"Perucca","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1528-1157.1996.tb00651.x","article-title":"Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy","volume":"37","author":"Sachdeo","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF42","first-page":"662","article-title":"Multiple-dose pharmacokinetics of topiramate in healthy male subjects","volume":"29","author":"Doose","year":"1988","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF43","first-page":"54","article-title":"Steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy","volume":"35 (suppl 8)","author":"Gisclon","year":"1994","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF44","first-page":"646","article-title":"Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate","volume":"30","author":"Floren","year":"1989","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF45","first-page":"152","article-title":"Topiramate: PK\/PD analyses","volume":"36 (suppl 3)","author":"Reife","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF46","series-title":"Poster presented at the 21st International Epilepsy Congress, Sydney, 3\u20138 September 1995","article-title":"The steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy","author":"Rosenfeld","year":"1995"},{"key":"10.1006\/phrs.1997.0124_FR970124RF47","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"The Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400 and 600mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1006\/phrs.1997.0124_FR970124RF48","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"The Topiramate YE Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800 and 1000mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"key":"10.1006\/phrs.1997.0124_FR970124RF49","first-page":"5","article-title":"Double-blind placebo-controlled trial of topiramate adjunctive therapy for partial-onset therapy","volume":"37 (suppl 4)","author":"Rosenfeld","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF50","first-page":"153","article-title":"Placebo controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy","volume":"37 (suppl 5)","author":"Rosenfeld","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF52","first-page":"149","article-title":"Double-blind, placebo-controlled trial of 400mg day\u22121","volume":"36 (suppl 3)","author":"Martinez-Lage","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF54","first-page":"17","article-title":"Clinical efficacy of topiramate: US and European experience","volume":"1","author":"Reife","year":"1995","journal-title":"Adv AED Ther"},{"key":"10.1006\/phrs.1997.0124_FR970124RF55","first-page":"72","article-title":"Topiramate: Intent-to-treat and other analyses","volume":"37 (suppl 4)","author":"Pledger","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF56","first-page":"74","article-title":"Topiramate: Pooled analysis of six placebo-controlled trials","volume":"37 (suppl 4)","author":"Reife","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF57","first-page":"152","article-title":"Long-term follow-up of patients treated with topiramate for partial seizures","volume":"36 (suppl 3)","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF58","first-page":"60","article-title":"Long-term, open-label study of topiramate in 15 patients with difficult-to-control epilepsy","volume":"37 (suppl 4)","author":"Binelli","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF59","first-page":"61","article-title":"Topiramate in the treatment of partial refractory partial epilepsy: An open-label study with long-term follow-up","volume":"37 (suppl 4)","author":"Canger","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF60","first-page":"152","article-title":"Topiramate as adjunctive therapy in patients with refractory epilepsy: A report of long-term, open-label study","volume":"36 (suppl 3)","author":"Cowell","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF61","first-page":"89","article-title":"Topiramate as add-on, open therapy in drug-resistant epilepsies: One year of follow-up","volume":"37 (suppl 4)","author":"Durisotti","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF62","first-page":"123","article-title":"Long-term effect of topiramate in refractory partial epilepsy","volume":"34 (suppl 2)","author":"Engelskjon","year":"1993","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF63","first-page":"56","article-title":"Long-term therapy with topiramate in patients with partial seizures","volume":"36 (suppl 4)","author":"Fincham","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF64","first-page":"67","article-title":"Canadian long-term experience with topiramate","volume":"37 (suppl 4)","author":"Guberman","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF65","first-page":"151","article-title":"Topiramate as add-on open therapy in patients with partial seizures","volume":"36 (suppl 3)","author":"Kugoh","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF66","first-page":"69","article-title":"Topiramate in drug-resistant partial and generalized epilepsies","volume":"37 (suppl 4)","author":"Leuf","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF67","first-page":"70","article-title":"Topiramate in the treatment of refractory epilepsy: A 2-year long-term follow-up","volume":"37 (suppl 4)","author":"Michelucci","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF68","first-page":"123","article-title":"Topiramate as long-term treatment in refractory partial epilepsy","volume":"34 (suppl 2)","author":"Mikkelsen","year":"1993","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF69","first-page":"55","article-title":"Efficacy and safety of topiramate in epilepsy","volume":"36 (suppl 4)","author":"Pavkovic","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF70","first-page":"152","article-title":"Long-term efficacy and safety of topiramate","volume":"36 (suppl 3)","author":"Privitera","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF71","first-page":"151","article-title":"Open add-on trial with topiramate (Topamax) in patients with partial epilepsy","volume":"36 (suppl 3)","author":"Proest","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF72","first-page":"234","article-title":"Topiramate: A new antiepileptic drug for complex partial seizures. First use in epileptic patients","volume":"38 (suppl 1)","author":"Rangel","year":"1988","journal-title":"Neurology"},{"key":"10.1006\/phrs.1997.0124_FR970124RF73","first-page":"44","article-title":"Topiramate (Topamax) add-on therapy in medically intractable epilepsy: Clinical features of cognitive effects","volume":"34 (suppl 6)","author":"Rak","year":"1993","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF01997718","article-title":"Efficacy and safety of topiramate in refractory epilepsy: A long-term prospective trial","volume":"17","author":"Tartara","year":"1996","journal-title":"Ital J Neurol Sci"},{"key":"10.1006\/phrs.1997.0124_FR970124RF75","first-page":"80","article-title":"Double-blind placebo-controlled trial of topiramate in refractory partial epilepsy with open-label continuation","volume":"37 (suppl 4)","author":"Walker","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF76","first-page":"251","article-title":"Efficacia e tollerabilita' di topiramato in terapia add-on: Analisi ad interim di uno studio aperto policentrico","volume":"95\/96","author":"Canger","year":"1996","journal-title":"Boll Lega It Epil"},{"key":"10.1006\/phrs.1997.0124_FR970124RF77","first-page":"56","article-title":"Topiramate in childhood epilepsy: Titration, adverse events, and efficacy in multiple seizure types","volume":"36 (suppl 4)","author":"Espe-Lillo","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF78","first-page":"118","article-title":"Topiramate in Lennox-Gastaut syndrome","volume":"37 (suppl 4)","author":"Sachdeo","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF79","first-page":"75","article-title":"Topiramate in childhood minor epileptic status","volume":"37 (suppl 4)","author":"Rossounis","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF80","first-page":"98","article-title":"Topiramate monotherapy substitution in children with partial epilepsy","volume":"37 (suppl 4)","author":"Glauser","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF81","first-page":"56","article-title":"Topiramate can be a successful monotherapy drug","volume":"36 (suppl 4)","author":"Rosenfeld","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF82","first-page":"62","article-title":"Topiramate monotherapy: Patient with refractory complex partial seizures becomes seizure-free","volume":"37 (suppl 4)","author":"Tigaran","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF83","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1528-1157.1997.tb01120.x","article-title":"Topiramate monotherapy for partial onset seizures","volume":"38","author":"Sachdeo","year":"1997","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1528-1157.1996.tb06029.x","article-title":"Safety of topiramate: Adverse events and relationships to dosing","volume":"37 (suppl 2)","author":"Shorvon","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF85","first-page":"24","article-title":"Safety of topiramate in clinical use","volume":"1","author":"Reife","year":"1995","journal-title":"Adv AED Ther"},{"key":"10.1006\/phrs.1997.0124_FR970124RF86","first-page":"34","article-title":"Topiramate: Side effect profile in double-blind studies","volume":"36 (suppl 4)","author":"Reife","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF87","series-title":"Side Effects of Drugs Annual 18","doi-asserted-by":"crossref","DOI":"10.1016\/S0378-6080(05)80251-X","article-title":"Anticonvulsant drugs","author":"Perucca","year":"1994"},{"key":"10.1006\/phrs.1997.0124_FR970124RF88","first-page":"153","article-title":"Investigation of the mechanistic basis for topiramate-associated nephrolithiasis: Examination of urine and plasma constituents","volume":"36 (suppl 3)","author":"Wasserstein","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF89","first-page":"153","article-title":"Nephrolithiasis during treatment with topiramate","volume":"36 (suppl 3)","author":"Wasserstein","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF90","first-page":"643","article-title":"Drug-induced myopia: A transient side effect of topiramate","volume":"31","author":"Schear","year":"1990","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF91","first-page":"34","article-title":"Topiramate well tolerated by pediatric patients","volume":"36 (suppl 4)","author":"Thanedar","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1528-1157.1996.tb06028.x","article-title":"Drug interaction profile of topiramate","volume":"37 (suppl 2)","author":"Bourgeois","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF93","first-page":"54","article-title":"Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy and during combination therapy","volume":"35 (suppl 8)","author":"Doose","year":"1994","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF94","first-page":"158","volume":"36 (suppl 3)","author":"Doose","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF95","first-page":"47","article-title":"Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum","volume":"36 (suppl 4)","author":"Levy","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF96","article-title":"Topiramate and phenytoin pharmacokinetics in patients with epilepsy during monotherapy and combination therapy","volume":"in press","author":"Sachdeo","year":"1997","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF97","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","article-title":"Comparison of the steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy during monotherapy and concomitant therapy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF98","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1528-1157.1997.tb01123.x","article-title":"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF99","unstructured":"Stahle, PL, Stellar, SM, Lucas, PN, Desai, DM, Takacs, AR, 1994, Topiramate-warfarin interaction in the dog, Abstract, Eastern Regional Meeting of the American Association of Pharmacologists"},{"key":"10.1006\/phrs.1997.0124_FR970124RF100","first-page":"444","article-title":"Digoxin and topiramate drug interaction study in male volunteers","volume":"11 (suppl)","author":"Liao","year":"1994","journal-title":"Pharm Res"},{"key":"10.1006\/phrs.1997.0124_FR970124RF101","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2125.1989.tb03469.x","article-title":"Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy","volume":"27 (suppl 1)","author":"Mumford","year":"1989","journal-title":"Brit J Clin Pharmacol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF102","first-page":"67","article-title":"Multicentre dose-response study of vigabatrin in adults with focal (partial) epilepsy","volume":"34 (suppl 6)","author":"Penry","year":"1993","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.46.1.54","article-title":"and the Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo-controlled study of vigabatrin 3g day\u22121","volume":"46","author":"French","year":"1996","journal-title":"Neurology"},{"key":"10.1006\/phrs.1997.0124_FR970124RF104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0920-1211(93)90011-U","article-title":"Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial","volume":"15","author":"Schmidt","year":"1993","journal-title":"Epilepsy Res"},{"key":"10.1006\/phrs.1997.0124_FR970124RF105","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/0140-6736(92)91207-O","article-title":"Lamotrigine","volume":"339","author":"Brodie","year":"1992","journal-title":"Lancet"},{"key":"10.1006\/phrs.1997.0124_FR970124RF106","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1212\/WNL.43.11.2284","article-title":"Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures","volume":"43","author":"Matsuo","year":"1993","journal-title":"Neurology"},{"key":"10.1006\/phrs.1997.0124_FR970124RF107","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1212\/WNL.41.11.1785","article-title":"Felbamate for partial seizures: Results of a controlled clinical trial","volume":"41","author":"Leppik","year":"1991","journal-title":"Neurology"},{"key":"10.1006\/phrs.1997.0124_FR970124RF108","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1528-1157.1991.tb04668.x","article-title":"Felbamate: A clinical trial for complex partial seizures","volume":"32","author":"Theodore","year":"1991","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF109","series-title":"Felbamate. A Novel Antiepileptic Agent","author":"Anonymous","year":"1993"},{"key":"10.1006\/phrs.1997.0124_FR970124RF110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1528-1157.1995.tb06010.x","article-title":"International experience with tiagabine add-on therapy","volume":"36 (suppl 6)","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF111","series-title":"New Trends in Epilepsy Management: The Role of Gabapentin","article-title":"Efficacy and safety of gabapentin","author":"Brown","year":"1993"},{"key":"10.1006\/phrs.1997.0124_FR970124RF112","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1528-1157.1996.tb06035.x","article-title":"The clinical use of new antiepileptic drugs. An overview of safety and efficacy","volume":"37 (suppl 6)","author":"Chadwick","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF113","series-title":"An Appraisal of Some New Anticonvulsants\u2013A Clinical Perspective","article-title":"Recipes for clinical practice","author":"Perucca","year":"1994"},{"key":"10.1006\/phrs.1997.0124_FR970124RF114","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: Advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"Brit J Clin Pharmacol"},{"key":"10.1006\/phrs.1997.0124_FR970124RF115","article-title":"Evaluation of drug treatment outcome in epilepsy: A clinical perspective","volume":"in press","author":"Perucca","year":"1997","journal-title":"Pharmacy World and Science"},{"key":"10.1006\/phrs.1997.0124_FR970124RF116","first-page":"118","article-title":"Topiramate. Effective dosaging enhances potential for success","volume":"33 (suppl 3)","author":"Rosenfeld","year":"1992","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF117","first-page":"5","article-title":"Comparison of two upward titration rates in initiation of therapy with topiramate","volume":"37 (suppl 4)","author":"Biton","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/phrs.1997.0124_FR970124RF118","unstructured":"Ben-Menachem, E, 1996, Preliminary results with topiramate in primary generalized seizures, Topiramate: Closing the Therapeutic Gap in Epilepsy. Satellite Symposium, Second European Congress of Epileptology, 3 September, European Congress of Epileptology, The Hague"},{"key":"10.1006\/phrs.1997.0124_FR970124RF119","first-page":"A176","article-title":"Topiramate (Topamax) as add-on therapy in primary generalized epilepsy","volume":"46","author":"Biton","year":"1996","journal-title":"Neurology"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661897901249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661897901249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T06:45:14Z","timestamp":1620024314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661897901249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["S1043661897901249"],"URL":"https:\/\/doi.org\/10.1006\/phrs.1997.0124","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[1997,4]]}}}